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Abstract
Background: Regional oximetry is increasingly used to monitor post-extraction oxygen status of the brain during
surgical procedures where hemodynamic fluctuations are expected. Particularly in cardiac surgery, clinicians employ
an interventional algorithm to restore baseline regional oxygen saturation (rSO2) when a patient reaches a critical
desaturation threshold. Evidence suggests that monitoring cardiac surgery patients and intervening to maintain
rSO2 can improve postoperative outcomes; however, evidence generated with one manufacturer’s device may not
be applicable to others. We hypothesized that regional oximeters from different manufacturers respond uniquely to
changes in oxygen saturation in healthy volunteers.
Methods: Three devices were tested: INVOS™ 5100C (Medtronic), EQUANOX™ 7600 (Nonin), and FORE-SIGHT™
(CASMED) monitors. We divided ten healthy subjects into two cohorts wearing a single sensor each from INVOS
and EQUANOX (n = 6), or INVOS and FORE-SIGHT (n = 4). We induced and reversed hypoxia by adjusting the
fraction of inspired oxygen. We calculated the magnitude of absolute rSO2 change and rate of rSO2 change during
desaturation and resaturation, and determined if and when each device reached a critical interventional rSO2
threshold during hypoxia.
Results: All devices responded to changes in oxygen directionally as expected. The median absolute rSO2 change
and the rate of rSO2 change was significantly greater during desaturation and resaturation for INVOS compared
with EQUANOX (P = 0.04). A similar but nonsignificant trend was observed for INVOS compared with FORE-SIGHT;
our study was underpowered to definitively conclude there was no difference. A 10% relative decrease in rSO2
during desaturation was detected by all three devices across the ten subjects. INVOS met a 20% relative decrease
threshold in all subjects of both cohorts, compared to 1 with EQUANOX and 2 with FORE-SIGHT. Neither EQUANOX
nor FORE-SIGHT reached a 50% absolute rSO2 threshold compared with 4 and 3 subjects in each cohort with
INVOS, respectively.
Conclusions: Significant differences exist between the devices in how they respond to changes in oxygen
saturation in healthy volunteers. We suggest caution when applying evidence generated with one manufacturer’s
device to all devices.
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Background
A recent publication reported that surveyed cardiac an-
esthesiologists and perfusionists view regional oximetry
as useful or essential for non-invasive monitoring of
cerebral oxygen status during surgery [1]. Rapidly chan-
ging hemodynamic conditions can cause cerebral desat-
uration during cardiac, arthroscopic shoulder, major
abdominal, and total knee replacement surgeries [2–5].
Originally published in 2007, clinicians continue to re-
fine an interventional algorithm for maintaining cerebral
oxygen saturation values (rSO2) close to baseline during
cardiac surgery by manipulating oxygen supply and de-
mand [6, 7]. Cerebral desaturation—often defined as a
20% relative decrease from baseline or an absolute rSO2
value of 50%—may trigger clinicians to consider a range
of possible interventions to restore oxygen saturation,
such as ruling out mechanical obstructions or increasing
mean arterial pressure [7]. Several cardiac studies sug-
gest postoperative outcomes may improve when cerebral
oxygen saturation is monitored and desaturation epi-
sodes are recognized and reversed, compared to no or
blinded monitoring [8–13].
We propose that published evidence generated with one
manufacturer’s regional oximeter is unique to that device
since they may reach an interventional threshold at differ-
ent times or not at all. Each manufacturer uses a propri-
etary algorithm, as well as different emitter/detector
spacing, number of wavelengths, and light source. We
hypothesize that regional oximeters will react differently to
clinically challenging situations where rSO2 is fluctuating.
To test our hypothesis, we subjected healthy volun-
teers to two cycles of desaturation and resaturation to
characterize the differences in absolute rSO2 change and
rate of rSO2 change between three FDA-cleared regional
oximeters: INVOS™ 5100C (Medtronic), EQUANOX™
7600 (Nonin), and FORE-SIGHT™ (CASMED) monitors.
Changes in rSO2 were compared with changes in oxygen
saturation as measured by pulse oximetry. Subjects wore
one sensor each from two devices. We also took a
unique approach from other comparative studies by
tracking the time in which the devices reached critical
rSO2 thresholds and whether the thresholds were met by
one or both devices in individual subjects.
Methods
The Western Institutional Review Board (Puyallup, WA)
approved an overarching protocol for a study of pulse
oximetry devices, of which this was studied under.
Written informed consent was obtained prior to participa-
tion. Twelve healthy subjects were enrolled from an exist-
ing hypoxia research pool and studied at the Medtronic
Respiratory & Monitoring Solutions clinical laboratory
(Boulder, CO) from April 16 to 18, 2013. Two subjects
were withdrawn: one failed screening, and the other
experienced tachycardia and anxiety during the study. The
study pool included males and non-pregnant or -lactating
females, 18 to 50 years of age, from various racial and
ethnic backgrounds, who tolerated hypoxia in previous
studies. Skin pigmentation was rated as very light, olive,
dark olive, or extremely dark.
Subjects reclined to approximately 20° in the supine
position with legs elevated. Peripheral capillary oxygen
saturation (SpO2) was monitored using the Nellcor
N600x™ and Max-A™ sensors (Medtronic, Dublin, Ireland)
on the middle and index fingers. Standard monitoring in-
cluded continuous electrocardiography, noninvasive blood
pressure, end-tidal carbon dioxide, and respiration rate.
We tested three FDA-cleared regional oximeters: INVOS
5100C (Medtronic, Dublin, Ireland), EQUANOX 7600
(Nonin Medical, Plymouth, MN), and FORE-SIGHT
(CASMED, Branford, CT). All devices report regional
oxygen saturation (rSO2) of the tissue beneath the sensor
based on near infrared spectroscopy, the technical aspects
of which are reported elsewhere [14, 15]. Two monitors
were tested per subject with one INVOS sensor (SAFB-
SM) on the left side of the forehead, and either an EQUA-
NOX (8000CA or 8004CA) or FORE-SIGHT (standard
large, medium, or small) sensor on the right, placed 2 cm
apart if possible (Fig. 1). Six were studied with INVOS and
EQUANOX, and four with INVOS and FORE-SIGHT.
Fig. 1 Placement of INVOS, EQUANOX, and FORE-SIGHT sensors
on healthy human volunteers. * 2 cm separation distance was
not possible in all subjects
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Subjects were fitted with a gas delivery mask, through
which the anesthesiologist adjusted the fraction of in-
spired oxygen (FiO2) using an oxygen-nitrogen gas
mixer. The hypoxia protocol used meets the guideline
defined in the ISO standard 80601-2-61:2011 for non-
invasive laboratory testing on healthy volunteers for
pulse oximetry, and is outlined in Fig. 2. (1) The initial
baseline readings were established while breathing room
air through the mask. (2) The FiO2 was decreased, based
on the subject’s tolerance, to achieve an SpO2 reading of
approximately 70%. (3) SpO2 was maintained at 70% for
at least 60 s after the reading plateaued, up to 5 min. (4)
The FiO2 was instantly increased to 1.0 to achieve a frac-
tion of exhaled oxygen concentration (FeO2) of at least
0.85. (5–9) Plateau measurements were collected, and
the desaturation cycle was repeated. (10) The mask was
removed, and data collection continued for 5 min with
the subject breathing room air. The anesthesiologist and
lab clinician monitored vital signs and subject comfort
throughout the experiment. Digital trending data from
all monitors were collected and time-stamped.
Statistical analyses were performed using Minitab 17
(Minitab, Inc, Sate College, PA). Baseline rSO2 and abso-
lute percent changes in SpO2 and rSO2 were graphed as
individual subject data and the median for each device
within the cohort. Rates of absolute oxygen saturation
change (% per minute) were reported as the median and
95% confidence interval (CI) for each device within the
cohort. Given the small sample size, normality was not
assumed and the Wilcoxon Signed-Rank test for paired
samples was used to assess significant differences in
baseline rSO2 values, absolute rSO2 changes, and rates
of rSO2 change between the devices within each cohort.
Significant differences between devices in detecting
critical rSO2 thresholds were assessed using the exact
binomial test. A P value of <0.05 was considered
statistically significant for all analyses.
Results
We performed two rounds of desaturation and resatura-
tion in ten healthy human subjects. The INVOS/EQUA-
NOX and INVOS/FORE-SIGHT cohorts were similar in
subject characteristics and gender distributions (Table 1).
We included Caucasian (70%) and Asian (30%) subjects
with a range of skin pigmentation from very light to dark
olive; no African Americans were available to participate.
Baseline rSO2 prior to desaturation
We plotted individual baseline rSO2 and median rSO2
values to visually compare the range and central ten-
dency for each device (Fig. 3). The median baseline rSO2
prior to desaturation trended higher for FORE-SIGHT
by approximately 10 percentage points compared with
INVOS, although the differences were not statistically
significant. Median INVOS and EQUANOX baseline
rSO2 values differed by less than 2 percentage points.
INVOS reported a wider range of individual baseline rSO2
values (54–93%) compared to EQUANOX (58–84%).
FORE-SIGHT reported a narrower range of baseline
values (69–81%) than both INVOS and EQUANOX.
Absolute % change in rSO2 during desaturation and
resaturation
INVOS reported a significantly greater median absolute
percent rSO2 change during both desaturation cycles com-
pared with EQUANOX (P = 0.04), with a trend towards a
greater change compared with FORE-SIGHT (P = 0.10)
(Fig. 4). Although we did not compare the values statisti-
cally, the absolute percent change reported by INVOS
(19.5–22.5%) followed closer in magnitude to the absolute
Fig. 2 Method for inducing desaturation and resaturation in healthy subjects. Desaturation was induced by adjusting the gas mixture of oxygen
and nitrogen through a facemask in healthy subjects. (1) Subjects breathed room air until a stable baseline rSO2 was achieved. (2–3) FiO2 was
titrated down slowly to achieve a stable plateau SpO2 of approximately 70%. (4–5) FiO2 was increased instantly to 1 to achieve a stable FeO2 of
0.85. Steps (6) through (9) represent a second desaturation and resaturation cycle, after which (10) the subjects were returned to room air
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changes in SpO2 (21.0–24.9%) compared with EQUA-
NOX (12.0–15.5%) and FORE-SIGHT (13.5–15.0%).
We discovered similar results during the two resatura-
tion cycles, although the difference in absolute percent
change in rSO2 for INVOS compared with EQUANOX
during resaturation #2 only trended towards significance
(P = 0.06) (Fig. 5).
Rate of rSO2 change during desaturation and resaturation
We report the rates of rSO2 change during desaturation
for each of the devices in Table 2, with SpO2 change
shown for comparison. For both desaturation cycles,
INVOS reported a significantly greater percent rSO2
change than EQUANOX (P = 0.04), with a trend towards
a greater change than FORE-SIGHT (P = 0.10). The
median rates of rSO2 change for INVOS (3.0–4.0%/min)
followed closer in magnitude to rates of SpO2 change
(3.6–4.3%/min) than EQUANOX (2.3–3.0%/min) or
FORE-SIGHT (2.2–2.4%/min).
The rate of rSO2 change during resaturation is
reported in Table 3. INVOS reported a significantly
greater rate of change compared with EQUANOX dur-
ing resaturation #1 (P = 0.04), with a trend towards a
greater rate during resaturation #2 (P = 0.06). Although
numerically higher than FORE-SIGHT, the rates of rSO2
change for INVOS during both resaturation cycles were
not statistically different. The median rates of rSO2 change
for INVOS (9.6–15.9%/min) were closer in magnitude to
rates of SpO2 change (11.75–19.1%/min) than EQUANOX
(9.2–11.2%/min) or FORE-SIGHT (6.6–9.5%/min).
Critical desaturation thresholds
We reviewed the rSO2 values from desaturation #1 for the
following thresholds: 1) 10% relative change from baseline,
2) 20% relative change from baseline, and 3) an absolute
value of 50%. For each subject, we determined whether
the devices reached the threshold, and the mean time
difference when the threshold was met by both devices.
We considered a 10% relative change from baseline as
an early indicator that cerebral oxygen saturation is
decreasing and may require early intervention [2]. All
three devices reached the 10% relative change in all
subjects of both cohorts. On average, INVOS reached
the 10% threshold 28 s earlier than EQUANOX, and
43 s earlier than FORE-SIGHT.
Table 1 Descriptive characteristics of study participants,





Age (yrs) 35.2 ± 10.2 31.8 ± 7.9
Male 3 (50%) 2 (50%)
Race/ethnicity
Asian 2 (33%) 1 (25%)
Caucasian 4 (67%) 3 (75%)
Skin pigmentation
Very light 4 (68%) 3 (75%)
Olive 1 (16%) 0 (0%)
Dark olive 1 (16%) 1 (25%)
Height (cm) 172.6 ± 4.7 176.6 ± 11.5
Weight (kg)a 75.1 ± 20.6 68.3 ± 7.1
aWeight was unavailable for one participant
Fig. 3 Individual baseline and median rSO2 values prior to desaturation #1 (a) and #2 (b). INVOS demonstrated a wider spread of individual
baseline values than both EQUANOX and FORE-SIGHT. Although the median FORE-SIGHT baseline rSO2 was consistently higher than INVOS by
approximately 10%, the differences were not statistically significant (two-tailed Wilcoxon Signed-Rank test for paired samples)
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Table 4 shows the number of subjects in which only one
monitor for each pair detected a critical drop in rSO2. In
the INVOS/EQUANOX cohort, INVOS met the 20% rela-
tive decrease for all six subjects in the cohort. In five of six
subjects, EQUANOX did not detect a 20% relative de-
crease. There were no subjects for whom EQUANOX
reached the threshold and INVOS did not, and although
numerically different, the results only trended towards stat-
istical significance (P = 0.06). We found similar results with
the INVOS/FORE-SIGHT cohort, where INVOS met the
20% threshold in all four subjects compared with two sub-
jects with FORE-SIGHT. There were no subjects for whom
FORE-SIGHT detected a 20% relative change when INVOS
did not. The difference was not statistically significant.
When we used an absolute threshold of 50%, INVOS
reached the threshold in four of six subjects, whereas
EQUANOX did not in any subjects, with a trend towards
statistical significance (P = 0.06). In the INVOS/FORE-
SIGHT cohort, INVOS reached the threshold in three of
four subjects, while FORE-SIGHT did not in any subjects.
Again, the results were not statistically significant.
Discussion
All three devices reported changes in rSO2 during the
course of desaturation and resaturation. We found that
the median absolute change in rSO2, and the rate of
rSO2 change per minute, was significantly greater with
INVOS compared with EQUANOX during desaturation.
The magnitude and rate of change was numerically
greater with INVOS compared to FORE-SIGHT, but the
differences were not statistically significant. When we
reversed desaturation, we found similar significant differ-
ences in the magnitude and rate of change between
INVOS and EQUANOX, with a trend towards signifi-
cance between INVOS and FORE-SIGHT.
The most interesting finding was the discordance in
detecting critical desaturation thresholds during desatur-
ation when comparing devices on the same subject. All
three technologies detected a minimum 10% relative
decrease in rSO2 from baseline in all subjects; EQUA-
NOX and FORE-SIGHT reached the threshold on aver-
age 28 to 43 s after INVOS, respectively. INVOS
detected a 20% relative decrease in rSO2 in all subjects
Fig. 4 Individual absolute and median rSO2 changes during desaturation #1 (a, b) and #2 (c, d). Absolute changes in SpO2, representing global
saturation, are shown for comparison. Median absolute change in rSO2 reported by INVOS during desaturation #1 and #2 were significantly
greater than that of EQUANOX. Although FORE-SIGHT reported a smaller median absolute change during desaturation #1 and #2 compared with
INVOS, the differences were not statistically significant (two-tailed Wilcoxon Signed-Rank test for paired samples). *Indicates statistical significance
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of both cohorts, compared to one with EQUANOX, and
two subjects with FORE-SIGHT. Neither EQUANOX
nor FORE-SIGHT met the 50% absolute rSO2 threshold
in any subjects, compared to four and three subjects
with INVOS, respectively. While our findings lacked
statistical significance, they may have important clinical
implications.
The randomized, controlled evidence reporting im-
proved postoperative outcomes compared with no moni-
toring is based on detecting a critical drop in rSO2 in
the monitored subjects that the clinician observes and
intervenes to reverse [4, 8–12]. These studies usually cite
a threshold of either a 20 to 25% relative decrease from
baseline, or absolute value of 50 to 60%. Our study has
shown that regardless of whether a relative or absolute
threshold is used, disparities may exist between devices
in detecting desaturation events. These disparities may
result in clinicians intervening, for example, earlier and/
or more often when using one device compared to
another. A clinician may employ cerebral oximetry to
Fig. 5 Individual absolute and median rSO2 changes during resaturation #1 (a, b) and #2 (c, d). Absolute changes in SpO2, representing global
saturation, are shown for comparison. Median absolute change in rSO2 reported by INVOS during resaturation #1 was significantly greater than
that of EQUANOX. Although FORE-SIGHT reported a smaller median absolute change during resaturation #1 and #2 compared with INVOS, the
differences were not statistically significant (two-tailed Wilcoxon Signed-Rank test for paired samples). Data are missing for one INVOX/EQUANOX
subject in graph C. *Indicates statistical significance





%/min %/min %/min P value
Desaturation #1 4.2 (2.7, 5.2) 3.5 (2.9, 4.3) 2.3 (1.7, 2.8) 0.04a




%/min %/min %/min P value
Desaturation #1 3.6 (2.9, 4.1) 3.0 (2.5, 3.5) 2.4 (1.8, 2.8) 0.10
Desaturation #2 3.7 (2.9, 5.0) 3.4 (2.4, 4.9) 2.2 (1.7, 4.0) 0.10
aIndicates statistical significance between devices (two-tailed Wilcoxon Signed-
Rank test for paired samples)
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improve outcomes and see different results from pub-
lished trials if the same device is not used. We make no
judgment about which device is “correct,” simply that
they are different from one another.
Device design may contribute to the differences in
reporting rSO2 during changes in cerebral oxygen satur-
ation. Manufacturers make unique assumptions of arter-
ial versus venous contribution of the tissue under the
sensor: 25/75 for INVOS, and 30/70 for EQUANOX and
FORE-SIGHT. Each device uses a distinct proprietary
algorithm. INVOS 5100C has a 2-wavelength LED light
source in the sensor, compared with a 3-wavelength
LED in EQUANOX 7600 and a 4-wavelength laser in
FORE-SIGHT. The devices also sample different tissue
depths due to individual sensor/detector spacing.
Our findings corroborate those published from previ-
ous device comparisons in both healthy subjects and
surgical patients, with some exceptions. Fellahi and col-
leagues found a greater percent maximum difference
from baseline with INVOS compared with EQUANOX
in healthy subjects during leg vascular occlusion tests
[16]. In 42 off-pump coronary artery bypass surgery
patients, Moerman and colleagues reported a greater
area under the curve for INVOS during desaturation
compared to FORE-SIGHT (−68%/s vs −39%/s) and only
a weak correlation in rSO2 values between the two
devices (r = 0.31) [17]. In contrast, Closhen and col-
leagues found similar changes in rSO2 between INVOS
and FORE-SIGHT in 35 patients moved into the beach-
chair position for arthroscopic shoulder surgery,
although the absolute change in rSO2 for both devices
during repositioning was minimal (10%) [18]. The
authors reported a stronger correlation in rSO2 values
between the two devices (r = 0.68) than Moerman and
colleagues. Both Moerman and Fellahi reported a wider
range of values from INVOS compared with FORE-
SIGHT and EQUANOX, respectively [16, 17].
Fellahi and colleagues also found significantly greater
rates of rSO2 change during desaturation (3.65%/min vs
2.36%/min) and resaturation (30.4 vs 16.8%/min) for
INVOS compared with EQUANOX, similar to our own
findings [16]. But Hyttel-Sorensen and colleagues re-
ported a steeper desaturation slope with EQUANOX
during arm vascular occlusion in 10 healthy volunteers
compared with INVOS and FORE-SIGHT [19].
Few studies compared how and when different devices
detect clinically relevant desaturation events. Pisano et
al., compared devices in cardiac surgery and reported
that INVOS detected 20 significant cerebral desaturation
events in four of ten patients, compared with three
events in one patient for EQUANOX (the same patient
in which INVOS detected five events) [20]. Unlike our
study, two sensors per device were placed bilaterally,
with one sensor pair placed above the other on the fore-
head. We cannot compare these results to ours since
Pisano et al., recorded rSO2 from only one device at a
time due to interference, and as such would not have
detected the same desaturation events. In Closhen’s
beach-chair study, INVOS reported one event of rSO2
less than 50% during positioning that was not reported
by FORE-SIGHT [18]. In a multicenter, randomized,
controlled study of high-risk cardiac surgery patients
where all three devices were used, Deschamps et al.,
found that INVOS detected on average 2.3 desaturation
events per patient, compared with 1.7 for EQUANOX,
and 1.5 for FORE-SIGHT, although only one device was
Table 3 Median rates (95% CI) of absolute oxygen saturation change during resaturation
SpO2 INVOS EQUANOX
INVOS/EQUANOX (n = 6) (%/min) (%/min) (%/min) P value
Resaturation #1 19.1 (13.8, 25.7) 15.9 (12.5, 18.5) 11.2 (7.0, 13.4) 0.04a
Resaturation #2 15.3 (11.6, 21.9) 12.7 (8.5, 17.7) 9.2 (5.2, 14.5) 0.06
SpO2 INVOS FORE-SIGHT
INVOS/FORE-SIGHT (n = 4) (%/min) (%/min) (%/min) P value
Resaturation #1 12.9 (10.1, 18.8) 10.6 (8.1, 19.3) 9.5 (6.5, 14.4) 0.10
Resaturation #2 11.7 (10.4, 13.1) 9.6 (5.8, 12.5) 6.6 (4.4, 12.0) 0.20
Data are unavailable for one INVOX/EQUANOX subject. a Indicates statistical significance between devices (two-tailed Wilcoxon Signed-Rank test for
paired samples)














20% relative rSO2 decrease from baseline met 5 (83%) 0 0.06 2 (50%) 0 0.50
50% absolute rSO2 threshold met 4 (67%) 0 0.06 3 (75%) 0 0.25
Data were not statistically significant (exact binomial test)
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used per patient so there were no direct comparisons of
detecting the same event [2].
We point out several important limitations in our
study for consideration. We were not able to place the
sensors 2 cm apart on all subjects, and we did not inves-
tigate whether there was interference between the de-
vices at close distances. We did not calculate a sample
size a priori based on a predetermined difference be-
tween devices in either the magnitude or rate of rSO2
change. In cases where we observed no significant differ-
ence between devices, we are unsure if there truly was
no difference, or if our study lacked sufficient power.
We tend to believe the latter, particularly with the 4-
subject INVOS/FORE-SIGHT cohort.
Also, we suggest interpreting differences in rSO2 rates
of change during desaturation in our study with caution;
the anesthesiologist titrated FiO2 gradually as the subject
tolerated it, which may introduce between-subject vari-
ation. Baseline rSO2 reported by INVOS was notably
lower in some subjects than EQUANOX and FORE-
SIGHT, potentially influencing whether a device reached
the 50% absolute rSO2 threshold during desaturation.
Also, unlike two of the papers cited here, we used each
device unilaterally [17, 20]. We concede that one device
could have reached a threshold earlier than (or in the
absence of ) another due to hemispheric differences.
Finally, we did not directly sample arterial and venous
blood for calculating a weighted saturation as a reference
to compare with rSO2 values. As such, we cannot com-
ment on which device best represented cerebral oxygen
status. But despite the small nature of our pilot study,
the hypoxia protocol reported here is repeatable and
widely used for validating regional oximeters for agency
approval. We generated intriguing preliminary results to
inform future hypotheses and hopefully generate interest
in larger, more comprehensive device comparisons.
With these preliminary results, one might consider
whether clinical evidence generated in one manufac-
turer’s regional oximetry device can be broadly applied
to similar devices from other manufacturers. The three
devices tested in our study reached critical interven-
tional rSO2 thresholds inconsistently in the same sub-
ject. Although the differences between devices in
detecting critical rSO2 thresholds were not statistically
significant, we argue that the results may have clinical
significance. A larger study with adequate power may
clarify our findings.
Conclusions
To the best of our knowledge, our report is the first to
show differences between INVOS and both FORE-
SIGHT and EQUANOX in detecting the same desatur-
ation event when subjects are monitored simultaneously.
With this knowledge, one should take care in broadly
applying evidence of improved patient outcomes to all
devices when a single manufacturer’s device is used in a
study. Larger studies in clinical settings are required to
investigate the clinical impact of this finding.
Additional files
Additional file 1: Raw data subject #2234. (XLSX 107 kb)
Additional file 2: Raw data subject #1228. (XLSX 123 kb)
Additional file 3: Raw data subject #1654. (XLSX 174 kb)
Additional file 4: Raw data subject #1657. (XLSX 122 kb)
Additional file 5: Raw data subject #1667. (XLSX 139 kb)
Additional file 6: Raw data subject #1791. (XLSX 116 kb)
Additional file 7: Raw data subject #1806. (XLSX 128 kb)
Additional file 8: Raw data subject #1824. (XLSX 118 kb)
Additional file 9: Raw data subject #2142. (XLSX 124 kb)
Additional file 10: Raw data subject #2174. (XLSX 112 kb)
Additional file 11: Tabulated data from all subjects. (XLSX 62 kb)
Abbreviations
FeO2: Fraction of exhaled oxygen; FiO2: Fraction of inhaled oxygen;
rSO2: Cerebral oxygen saturation; SpO2: Peripheral capillary oxygen saturation
Acknowledgements
The authors recognize Monika Deshpande, MSc, for helping to coordinate
the study, recruit subjects, obtain informed consent, and collect data;
Yu-Jung Pinto, MSc, for providing all data in synchronized formats; Zengri
Wang, PhD, for review of the statistical analyses; and Michael Mestek, PhD,
for critical review of the manuscript.
Funding
Medtronic funded the study. Medtronic employees designed the study;
collected, analyzed, and interpreted the data; and wrote the manuscript.
Availability of data and materials
Datasets have been provided as Additional files 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11
as part of the manuscript submission.
Authors’ contributions
AMN and UB developed the protocol, coordinated the study, recruited
subjects, and gathered informed consent; collected and interpreted data;
and helped to critically revise the manuscript. KLT helped interpret and
analyze the data, performed statistical analyses, wrote the first draft and
revised subsequent drafts of the manuscript. All authors have read and
approved of the final manuscript.
Authors’ information
All authors are employees of the Patient Monitoring & Recovery Medical
Affairs Department at Medtronic (Boulder, Colorado, USA). KLT is a Medical
Affairs Program Manager and holds a PhD in cellular, molecular, and
microbial biology. AMN is a Clinical Program Manager holds an MD with a
specialty in general medicine. UB is the Director of Clinical Science and a
Registered Respiratory Therapist with extensive clinical experience in critical
care, and human and animal research.
Competing interests




Ethics approval and consent to participate
The Western Institutional Review Board (Puyallup, WA) approved an
overarching protocol for a study of pulse oximetry devices, under which this
Tomlin et al. BMC Anesthesiology  (2017) 17:6 Page 8 of 9
was a substudy (protocol #070808; Non-invasive Controlled Acute Hypoxia
Studies). We obtained informed consent from all subjects prior to participating
in the study.
Received: 24 August 2016 Accepted: 27 December 2016
References
1. Zacharias DG, Lilly K, Shaw CL, Pirundini P, Rizzo RJ, Body SC, Longford NT.
Survey of the clinical assessment and utility of near-infrared cerebral
oximetry in cardiac surgery. J Cardiothorac Vasc Anesth. 2014;28(2):308–16.
2. Deschamps A, Hall R, Grocott H, Mazer CD, Choi PT, Turgeon A, de Medicis
E, Bussieres JS, Hudson C, Syed S, et al. Cerebral Oximetry Monitoring to
Maintain Normal Cerebral Oxygen Saturation during High-risk Cardiac
Surgery: A Randomized Controlled Feasibility Trial. Anesthesiology. 2016;
124(4):826–36.
3. Pant S, Bokor DJ, Low AK. Cerebral oxygenation using near-infrared
spectroscopy in the beach-chair position during shoulder arthroscopy
under general anesthesia. Arthroscopy. 2014;30(11):1520–7.
4. Casati A, Fanelli G, Pietropaoli P, Proietti R, Tufano R, Danelli G, Fierro G, De
Cosmo G, Servillo G. Continuous monitoring of cerebral oxygen saturation
in elderly patients undergoing major abdominal surgery minimizes brain
exposure to potential hypoxia. Anesth Analg. 2005;101(3):740–7. table of
contents.
5. Salazar F, Donate M, Boget T, Bogdanovich A, Basora M, Torres F, Gracia I,
Fabregas N. Relationship between intraoperative regional cerebral oxygen
saturation trends and cognitive decline after total knee replacement: a post-
hoc analysis. BMC Anesthesiol. 2014;14:58.
6. Denault A, Deschamps A, Murkin JM. A proposed algorithm for the
intraoperative use of cerebral near-infrared spectroscopy. Semin
Cardiothorac Vasc Anesth. 2007;11(4):274–81.
7. Denault A, Lamarche Y, Rochon A, Cogan J, Liszkowski M, Lebon JS, Ayoub
C, Taillefer J, Blain R, Viens C, et al. Innovative approaches in the
perioperative care of the cardiac surgical patient in the operating room and
intensive care unit. Can J Cardiol. 2014;30(12 Suppl):S459–77.
8. Kara I, Erkin A, Sacli H, Demirtas M, Percin B, Diler MS, Kirali K. The Effects of
Near-Infrared Spectroscopy on the Neurocognitive Functions in the Patients
Undergoing Coronary Artery Bypass Grafting with Asymptomatic Carotid
Artery Disease: A Randomized Prospective Study. Ann Thorac Cardiovasc
Surg. 2015;21(6):544–50.
9. Vretzakis G, Georgopoulou S, Stamoulis K, Tassoudis V, Mikroulis D, Giannoukas
A, Tsilimingas N, Karanikolas M. Monitoring of brain oxygen saturation (INVOS)
in a protocol to direct blood transfusions during cardiac surgery: a prospective
randomized clinical trial. J Cardiothorac Surg. 2013;8:145.
10. Colak Z, Borojevic M, Bogovic A, Ivancan V, Biocina B, Majeric-Kogler V.
Influence of intraoperative cerebral oximetry monitoring on neurocognitive
function after coronary artery bypass surgery: a randomized, prospective
study. Eur J Cardiothorac Surg. 2015;47(3):447–54.
11. Mohandas BS, Jagadeesh AM, Vikram SB. Impact of monitoring cerebral
oxygen saturation on the outcome of patients undergoing open heart
surgery. Ann Card Anaesth. 2013;16(2):102–6.
12. Murkin JM, Adams SJ, Novick RJ, Quantz M, Bainbridge D, Iglesias I, Cleland
A, Schaefer B, Irwin B, Fox S. Monitoring brain oxygen saturation during
coronary bypass surgery: a randomized, prospective study. Anesth Analg.
2007;104(1):51–8.
13. Murkin JM, Adams SJ, Pardy E, Quantz M, McKenzie FN, Guo L. Monitoring
brain oxygen saturation during coronary bypass surgery improves
outcomes in diabetic patients: a post hoc analysis. Heart Surg Forum. 2011;
14(1):E1–6.
14. Ghosh A, Elwell C, Smith M. Review article: cerebral near-infrared spectroscopy
in adults: a work in progress. Anesth Analg. 2012;115(6):1373–83.
15. Steppan J, Hogue Jr CW. Cerebral and tissue oximetry. Best Pract Res Clin
Anaesthesiol. 2014;28(4):429–39.
16. Fellahi JL, Butin G, Fischer MO, Zamparini G, Gerard JL, Hanouz JL.
Dynamic evaluation of near-infrared peripheral oximetry in healthy
volunteers: a comparison between INVOS and EQUANOX. J Crit Care.
2013;28(5):881.e881–886.
17. Moerman A, Vandenplas G, Bove T, Wouters PF, De Hert SG. Relation
between mixed venous oxygen saturation and cerebral oxygen saturation
measured by absolute and relative near-infrared spectroscopy during off-
pump coronary artery bypass grafting. Br J Anaesth. 2013;110(2):258–65.
18. Closhen D, Berres M, Werner C, Engelhard K, Schramm P. Influence of beach
chair position on cerebral oxygen saturation: a comparison of INVOS and
FORE-SIGHT cerebral oximeter. J Neurosurg Anesthesiol. 2013;25(4):414–9.
19. Hyttel-Sorensen S, Hessel TW, Greisen G. Peripheral tissue oximetry:
comparing three commercial near-infrared spectroscopy oximeters on the
forearm. J Clin Monit Comput. 2014;28(2):149–55.
20. Pisano A, Galdieri N, Iovino TP, Angelone M, Corcione A. Direct comparison
between cerebral oximetry by INVOS(TM) and EQUANOX(TM) during cardiac
surgery: a pilot study. Heart Lung Vessel. 2014;6(3):197–203.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Tomlin et al. BMC Anesthesiology  (2017) 17:6 Page 9 of 9
